## Citation on the outstanding research work carried out by Prof Diwan S. Rawat

Prof. Diwan S. Rawat has made significant contributions to drug development and catalysis. He used the molecular hybridization concept to design new chemical entities and demonstrated that the resulting hybrids could improve biological activity. This work has led to the discovery of low nanomolar in vitro and in vivo antimalarial and anti-Parkinson molecules with no toxicity. A massive collaborative work resulted in the identification of many hybrids as Nurr1 activators and showed potent anti-Parkinson activity (US 11,026,943) B2/2021; US 0023930 A1, 2017; ES2899730T3, 2022; EP2822936B1, 2021; CA3175047A1, **2022**), and it resulted in a publication in **Nature Communication 2023**. The technology has been transferred to NurrON pharmaceuticals for the development of a drug for the treatment of Parkinson's disease, and NurrOn entered into a co-development agreement with HanAll Biopharma and Daewoong Pharmaceuticals to develop ATH-399A for Parkinson's disease. Phase I clinical trials of these molecules started in October 2023, and it has been funded by MJ Fox Foundation (https://nurronpharma.com/media-relation). Prof Rawat has also made significant contributions to catalyst design and its use in synthesizing biologically active, industrially important molecules and API, resulting in publications in high-impact journals such as ACS Sustainable Chem. Engg. ChemCatChem, Adv. Synth. Catal.; Green Chem.

Prof Rawat has published 169 research papers with over 7250 citations, an h-index of 50, and an i-10 index of 135. He has twelve patents, a book, and six chapters to his credit. The book "Bioactive Marine Natural Products" was published by Springer and reviewed by the Journal of American Society (J. Am. Chem. Soc. 128, 4494, 2006). Professor Rawat is an excellent teacher, and he has developed YouTube lectures on Organic Spectroscopy, which has over 25000 viewers and about 4500 subscribers.

<u> ۱۲۲</u>۱۷

Professor Vinod K Singh